Present Therapies and Rising Medication within the Prediabetes

0
392

Los Angeles, United States, June 2, 2021 (GLOBE NEWSWIRE) – Current therapies and new drugs in the prediabetes pipeline will soon improve the treatment outlook

Prominent companies like Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to advance the prediabetes treatment scenario. Of all emerging therapies, the late-stage product TOTUM-63 (VALBIOTIS) has shown promising results and will have a significant impact on the market for the treatment of prediabetes.

DelveInsight’s Prediabetes Pipeline Insight report provides deep insights into over 10 companies and over 10 pipeline drugs in the pipeline landscape. It includes drug profiles from the prediabetes pipeline, including clinical and non-clinical products. It also includes ratings of prediabetes therapeutics by product type, stage, route of administration, and molecule type, and further highlights the inactive prediabetes pipeline products.

Some of the key takeaways from the Prediabetes Pipeline Report

  • Notable companies like Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to advance the prediabetes treatment scenario.
  • In February 2020, VALBIOTIS signed a global and long-term partnership with Nestlé Health Science. Under the terms of the agreement, VALBIOTIS grants Nestlé Health Science the exclusive worldwide commercial rights to use TOTUM-63 in the prediabetes and type 2 diabetes markets.
  • Patent applications for TOTUM-63 (VALBIOTIS) have been filed in more than 60 countries, including key areas: Europe, USA, Canada, China, Russia, Japan, Brazil and Australia. The patent was granted in France in 2014, in the USA in 2018, in Europe (39 countries) in 2019 and in Russia in 2020.
  • Apabetalone (RVX-208) is a premium, low molecular weight selective BET bromodomain inhibitor. Inhibiting the BET bromodomain is an epigenetic mechanism that can turn off disease-causing genes and restore them to a healthier state. The drug has completed Phase II clinical trials for the treatment of prediabetes.
  • Anaerostipes rhamnosivorans from Caelus Health is a newly identified microorganism and is indicated as an intervention in metabolic syndrome. The product is currently in preclinical studies for the treatment of prediabetes.
  • SciMar is developing NuPa Renew for people who have already been diagnosed with type 2 diabetes or prediabetes. This medicine will activate the production of hepatic insulin sensitizing substance (HISS). For some people, NuPa Renew will be able to reverse type 2 diabetes by addressing the underlying biological conditions that caused it.

Get an overview of the @ Prediabetes Clinical Trials Analysis pipeline landscape

Prediabetes is a metabolic disease that is considered a precursor to the development of diabetes mellitus. It is characterized by a blood sugar level that is above normal and has not yet reached diabetic values.

Prediabetes New Drugs

TOTUM-63 is a unique and patented combination of 5 plant extracts designed to reduce the risk of developing T2D in prediabetic patients. TOTUM-63 is designed to challenge the perception of prediabetic management and protect the health of prediabetic patients. TOTUM-63 is currently in the phase II / III clinical development program for the treatment of prediabetes.

Research and Development
Phase II / III
NCT02868177: In October 2016, Valbiotis started a study entitled “Totum-63 Effect on Glucose and Lipid Homeostasis in People with Abdominal Obesity Associated with Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia”. The primary objective of the study was to evaluate the beneficial effects of Totum-63 versus placebo on glucose homeostasis, as assessed by fasting plasma glucose levels in prediabetic or untreated type 2 diabetic subjects after 24 weeks of use. The study was completed in April 2019.

Results:
In July 2019, VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active ingredient: TOTUM-63), in which the effectiveness of this product was compared to placebo in a prediabetic population.

  • Eubacterium hallii: Caelus Health

Eubacterium hallii is a microbiota-based dietary supplement currently being clinically treated in patients with metabolic syndrome / prediabetes. The product is in Phase II clinical development for the treatment of prediabetes.

Research and Development
NCT04529473: In August 2020, Caelus Health initiated a study entitled “A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Eubacterium Hallii Supplementation for 12 Week on Insulin Sensitivity and Markers of Glycemic Control in Healthy Hyperglycemic Men” “. This study aims to examine the effect of administering a next generation probiotic, Eubacterium hallii, compared to placebo on insulin sensitivity and glycemic control in volunteers with some markers of metabolic syndrome. The study is currently recruiting with an estimated enrollment of 100 participants and is expected to be completed in January 2022.

For more information, see the detailed report @ Prediabetes Pipeline Therapeutics

Amount of drug insight in the prediabetes pipeline

  • Coverage: Global
  • Main Players: 10+ main players
  • Celebrity Players: Valbiotis, Resverlogix, Caelus Health, SciMar, MicroBiome Therapeutics, Boston Therapeutics, and many others.
  • Key drug profiles: 10+ products
  • Phases:
  • Late-stage prediabetes therapies (phase III)
  • Mid-stage prediabetes therapies (phase II)
  • Early-stage prediabetes therapies (phase I)
  • Prediabetes Preclinical Stage and Discovery Candidates
  • Abandoned and inactive candidates
  • Protein Inhibitors of the Extra Terminal Domain
  • Tumor necrosis factor alpha inhibitors
  • Bromodomain and extra terminal domain protein inhibitors
  • Virus internalization inhibitors
  • Gastrointestinal microbiome modulators
  • Strain gene therapy
  • bacteria
  • Biologically
  • Monotherapy
  • combination
  • Mono / combination

Key questions about the current treatment landscape for prediabetes and emerging therapies that were answered in the pipeline report

  • What are the current options for treating prediabetes?
  • How many companies are developing therapies to treat prediabetes?
  • How many new therapies for early, middle, and late developmental prediabetes are there to treat prediabetes?
  • What are the most important collaborations (industrial-industry, industrial-science), mergers and acquisitions, and significant licensing activities that will affect the prediabetes market?
  • What are the dormant and discontinued products and the reasons for them?
  • What is the unmet need for current therapies to treat prediabetes?
  • What are the current novel therapies, goals, mechanisms of action, and technologies that have been developed to overcome the limitations of existing prediabetes therapies?
  • What are the critical names given to the new therapies for prediabetes?
  • How many patents have been granted and pending for the emerging therapies for treating prediabetes?

Table of Contents

1 Introduction to the Prediabetes Report
2 Prediabetes Summary
3 Prediabetes overview
4th Prediabetes – In-depth commercial evaluation of DelveInsight’s analytical perspective
5 Prediabetes pipeline therapeutics
6th Mid-stage prediabetes products (phase II / III)
6.1 All-63: Valbiotis
7th Prediabetes Mid-Stage Products (Phase II)
7.1 Apabetalone: ​​Resverlogix
8th Early stage prediabetes products (phase I)
8.1 Drug Name: Company Name
9 Prediabetes products for the preclinical phase
9.1 Anaerostipes rhamnosivorans: Caelus Health
10 Therapeutic evaluation of prediabetes
11 Prediabetes inactive products
12th Analysis of the cooperation between company and university (licensing / partnering)
13th Prediabetes key companies
14th Prediabetes key products
fifteen Prediabetes Unmet Needs
16 Market drivers and barriers for prediabetes
17th Prediabetes Future Perspectives and Conclusions
18th Prediabetes analyst views
19th appendix
20th About DelveInsight

Get a custom pipeline report @ Prediabetes Drugs Pipeline Report

Related reports

DelveInsight’s Prediabetes – Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth look at the disease and an in-depth understanding of its historical and predicted epidemiology.

DelveInsight’s Prediabetes – Epidemiology Forecast 2030 report provides an in-depth understanding of the disease, historical, and predicted epidemiology of prediabetes in the United States, EU5 (Germany, France, Italy, Spain and the UK) and Japan.

DelveInsight’s “Multiple Organ Dysfunction Syndrome Market Report 2030” provides an in-depth understanding, historical and forecasted epidemiology and market trends in the 7MM.

Corneal Endothelial Dystrophy – Market Insights, Epidemiology, and Market Forecast – 2030 by DelveInsight report provides in-depth insights into the historical and forecasted epidemiology.

DelveInsight’s Onychomycosis – Market Insights, Epidemiology and Market Forecast – 2030 report provides an overview and understanding of historical and forecasted epidemiology.

DelveInsight’s Deep Vein Thrombosis Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of the historical and predicted epidemiology in 7MM.

About DelveInsight
DelveInsight is a leading management consulting and research firm focused solely on the life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also provides health advisory services that include credible market analysis that will help accelerate business growth and overcome challenges with a hands-on approach.